{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T23:24:11Z","timestamp":1772839451316,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,12,3]],"date-time":"2023-12-03T00:00:00Z","timestamp":1701561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,3]],"date-time":"2023-12-03T00:00:00Z","timestamp":1701561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"JST grants from JSPS KAKENHI Grants-in-Aid","award":["Scientific Research (C) (H.K. 17K11445)"],"award-info":[{"award-number":["Scientific Research (C) (H.K. 17K11445)"]}]},{"name":"JST grants","award":["COI-NEXT (JPMJPF2201)."],"award-info":[{"award-number":["COI-NEXT (JPMJPF2201)."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-023-02870-4","type":"journal-article","created":{"date-parts":[[2023,12,3]],"date-time":"2023-12-03T19:02:00Z","timestamp":1701630120000},"page":"4701-4709","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Baseline characteristics associated with the incidence of intraocular inflammation after the intravitreous injection of brolucizumab"],"prefix":"10.1007","volume":"43","author":[{"given":"Keisuke","family":"Hoshi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kunikata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Aizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsu","family":"Okabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Takizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,3]]},"reference":[{"key":"2870_CR1","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X et al (2014) Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2:e106\u2013e116","journal-title":"Lancet Glob Health"},{"key":"2870_CR2","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","volume":"392","author":"P Mitchell","year":"2018","unstructured":"Mitchell P, Liew G, Gopinath B, Wong TY (2018) Age-related macular degeneration. Lancet 392:1147\u20131159","journal-title":"Lancet"},{"key":"2870_CR3","doi-asserted-by":"crossref","unstructured":"Wormald R, Evans J, Smeeth L, Henshaw K (2007) Photodynamic therapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev CD002030.","DOI":"10.1002\/14651858.CD002030.pub3"},{"key":"2870_CR4","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432\u20131444","journal-title":"N Engl J Med"},{"key":"2870_CR5","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","volume":"120","author":"S Rofagha","year":"2013","unstructured":"Rofagha S, Bhisitkul RB, Boyer DS et al (2013) Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 120:2292\u20132299","journal-title":"Ophthalmology"},{"key":"2870_CR6","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.oret.2019.01.018","volume":"3","author":"PG Traine","year":"2019","unstructured":"Traine PG, Pfister IB, Zandi S et al (2019) Long-term outcome of intravitreal aflibercept treatment for neovascular age-related macular degeneration using a \u201ctreat-and-extend\u201d regimen. Ophthalmol Retina 3:393\u2013399","journal-title":"Ophthalmol Retina"},{"key":"2870_CR7","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.ophtha.2019.12.031","volume":"127","author":"QD Nguyen","year":"2020","unstructured":"Nguyen QD, Das A, Do DV et al (2020) Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration. Ophthalmology 127:963\u2013976","journal-title":"Ophthalmology"},{"key":"2870_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","volume":"128","author":"PU Dugel","year":"2021","unstructured":"Dugel PU, Singh RP, Koh A et al (2021) HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 128:89\u201399","journal-title":"Ophthalmology"},{"key":"2870_CR9","doi-asserted-by":"publisher","first-page":"6759","DOI":"10.1038\/s41598-021-86014-7","volume":"11","author":"H Matsumoto","year":"2021","unstructured":"Matsumoto H, Hoshino J, Mukai R et al (2021) Short-term outcomes of intravitreal brolucizumab for treatment-na\u00efve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy. Sci Rep 11:6759","journal-title":"Sci Rep"},{"key":"2870_CR10","doi-asserted-by":"crossref","unstructured":"Haensli C, Pfister IB, Garweg JG (2021) Switching to brolucizumab in neovascular age-related macular degeneration incompletely responsive to ranibizumab or aflibercept: real-life 6 month outcomes. J Clin Med 10","DOI":"10.3390\/jcm10122666"},{"key":"2870_CR11","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","volume":"128","author":"J Mon\u00e9s","year":"2021","unstructured":"Mon\u00e9s J, Srivastava SK, Jaffe GJ et al (2021) Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER. Ophthalmology 128:1050\u20131059","journal-title":"Ophthalmology"},{"key":"2870_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2020.100680","volume":"18","author":"SJ Haug","year":"2020","unstructured":"Haug SJ, Hien DL, Uludag G et al (2020) Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration. Am J Ophthalmol Case Rep 18:100680","journal-title":"Am J Ophthalmol Case Rep"},{"key":"2870_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2020.100687","volume":"18","author":"A Jain","year":"2020","unstructured":"Jain A, Chea S, Matsumiya W et al (2020) Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations. Am J Ophthalmol Case Rep 18:100687","journal-title":"Am J Ophthalmol Case Rep"},{"key":"2870_CR14","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1007\/s00417-021-05518-0","volume":"260","author":"R Khoramnia","year":"2022","unstructured":"Khoramnia R, Figueroa MS, Hattenbach L-O et al (2022) Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular AMD. Graefes Arch Clin Exp Ophthalmol 260:1843\u20131856","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2870_CR15","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.oret.2020.09.020","volume":"5","author":"CR Baumal","year":"2021","unstructured":"Baumal CR, Bodaghi B, Singer M et al (2021) Expert opinion on management of intraocular inflammation, retinal vasculitis, and vascular occlusion after Brolucizumab treatment. Ophthalmol Retina 5:519\u2013527","journal-title":"Ophthalmol Retina"},{"key":"2870_CR16","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1001\/archopht.117.11.1503","volume":"117","author":"LA Yannuzzi","year":"1999","unstructured":"Yannuzzi LA, Wong DW, Sforzolini BS et al (1999) Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration. Arch Ophthalmol 117:1503\u20131510","journal-title":"Arch Ophthalmol"},{"key":"2870_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ajo.2007.03.047","volume":"144","author":"I Maruko","year":"2007","unstructured":"Maruko I, Iida T, Saito M et al (2007) Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 144:15\u201322","journal-title":"Am J Ophthalmol"},{"key":"2870_CR18","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/00006982-200510001-00001","volume":"25","author":"LJ Singerman","year":"2005","unstructured":"Singerman LJ, Brucker AJ, Jampol LM et al (2005) Neovascular age-related macular degeneration: roundtable. Retina 25:S1\u2013S22","journal-title":"Retina"},{"key":"2870_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/IAE.0000000000001496","volume":"38","author":"D Barthelmes","year":"2018","unstructured":"Barthelmes D, Nguyen V, Daien V et al (2018) Two year outcomes of \u201ctreat and extend\u201d intravitreal therapy using Aflibercept preferentially for Neovascular age-related macular degeneration. Retina 38:20\u201328","journal-title":"Retina"},{"key":"2870_CR20","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ophtha.2014.07.041","volume":"122","author":"K Berg","year":"2015","unstructured":"Berg K, Pedersen TR, Sandvik L, Bragad\u00f3ttir R (2015) Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology 122:146\u2013152","journal-title":"Ophthalmology"},{"key":"2870_CR21","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.ajo.2009.04.001","volume":"148","author":"SY Cohen","year":"2009","unstructured":"Cohen SY, Dubois L, Tadayoni R et al (2009) Results of one-year\u2019s treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. Am J Ophthalmol 148:409\u2013413","journal-title":"Am J Ophthalmol"},{"key":"2870_CR22","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0161-6420(95)30976-1","volume":"102","author":"Y Guex-Crosier","year":"1995","unstructured":"Guex-Crosier Y, Pittet N, Herbort CP (1995) Sensitivity of laser flare photometry to monitor inflammation in uveitis of the posterior segment. Ophthalmology 102:613\u2013621","journal-title":"Ophthalmology"},{"key":"2870_CR23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0161-6420(97)30359-5","volume":"104","author":"CP Herbort","year":"1997","unstructured":"Herbort CP, Guex-Crosier Y, de Ancos E, Pittet N (1997) Use of laser flare photometry to assess and monitor inflammation in uveitis. Ophthalmology 104:64\u201371","journal-title":"Ophthalmology"},{"key":"2870_CR24","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1159\/000513048","volume":"244","author":"R Tadayoni","year":"2021","unstructured":"Tadayoni R, Sararols L, Weissgerber G et al (2021) Brolucizumab: a newly developed anti-VEGF molecule for the treatment of neovascular age-related macular degeneration. Ophthalmologica 244:93\u2013101","journal-title":"Ophthalmologica"},{"key":"2870_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0259879","volume":"16","author":"R Mukai","year":"2021","unstructured":"Mukai R, Matsumoto H, Akiyama H (2021) Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration. PLoS ONE 16:e0259879","journal-title":"PLoS ONE"},{"key":"2870_CR26","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1007\/s00417-021-05136-w","volume":"259","author":"I Maruko","year":"2021","unstructured":"Maruko I, Okada AA, Iida T et al (2021) Brolucizumab-related intraocular inflammation in Japanese patients with age-related macular degeneration: a short-term multicenter study. Graefes Arch Clin Exp Ophthalmol 259:2857\u20132859","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2870_CR27","doi-asserted-by":"publisher","first-page":"60285","DOI":"10.1155\/MI\/2006\/60285","volume":"2006","author":"S Rossi","year":"2006","unstructured":"Rossi S, D\u2019Amico M, Capuano A et al (2006) Hyperglycemia in streptozotocin-induced diabetes leads to persistent inflammation and tissue damage following uveitis due to reduced levels of ciliary body heme oxygenase-1. Mediators Inflamm 2006:60285","journal-title":"Mediators Inflamm"},{"key":"2870_CR28","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1136\/bjo.2009.160986","volume":"94","author":"M Shimura","year":"2010","unstructured":"Shimura M, Yasuda K (2010) Macular ischaemia after intravitreal bevacizumab injection in patients with central retinal vein occlusion and a history of diabetes and vascular disease. Br J Ophthalmol 94:381\u2013383","journal-title":"Br J Ophthalmol"},{"key":"2870_CR29","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","volume":"127","author":"CR Baumal","year":"2020","unstructured":"Baumal CR, Spaide RF, Vajzovic L et al (2020) Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab. Ophthalmology 127:1345\u20131359","journal-title":"Ophthalmology"},{"key":"2870_CR30","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1177\/2474126420930863","volume":"4","author":"AJ Witkin","year":"2020","unstructured":"Witkin AJ, Hahn P, Murray TG et al (2020) Occlusive retinal vasculitis following intravitreal brolucizumab. J Vitreoretin Dis 4:269\u2013279","journal-title":"J Vitreoretin Dis"},{"key":"2870_CR31","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1001\/jamaophthalmol.2019.0010","volume":"137","author":"Y Subhi","year":"2019","unstructured":"Subhi Y, Krogh Nielsen M, Molbech CR et al (2019) Association of CD11b+ monocytes and anti-vascular endothelial growth factor injections in treatment of neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. JAMA Ophthalmol 137:515\u2013522","journal-title":"JAMA Ophthalmol"},{"key":"2870_CR32","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s10792-009-9310-2","volume":"30","author":"I Tugal-Tutkun","year":"2010","unstructured":"Tugal-Tutkun I, Herbort CP (2010) Laser flare photometry: a noninvasive, objective, and quantitative method to measure intraocular inflammation. Int Ophthalmol 30:453\u2013464","journal-title":"Int Ophthalmol"},{"key":"2870_CR33","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3109\/09273948.2015.1032308","volume":"24","author":"R Agrawal","year":"2016","unstructured":"Agrawal R, Keane PA, Singh J et al (2016) Comparative analysis of anterior chamber flare grading between clinicians with different levels of experience and semi-automated laser flare photometry. Ocul Immunol Inflamm 24:184\u2013193","journal-title":"Ocul Immunol Inflamm"},{"key":"2870_CR34","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s00417-008-0823-6","volume":"246","author":"I Tugal-Tutkun","year":"2008","unstructured":"Tugal-Tutkun I, Cing\u00fc K, Kir N et al (2008) Use of laser flare-cell photometry to quantify intraocular inflammation in patients with Beh\u00e7et uveitis. Graefes Arch Clin Exp Ophthalmol 246:1169\u20131177","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2870_CR35","first-page":"1425","volume":"17","author":"S Jiang","year":"2011","unstructured":"Jiang S, Liu X, Luo L et al (2011) Serum levels of Th17-related cytokines in Behcet disease patients after cataract surgery. Mol Vis 17:1425\u20131430","journal-title":"Mol Vis"},{"key":"2870_CR36","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/S0002-9394(01)01269-7","volume":"133","author":"H Funatsu","year":"2002","unstructured":"Funatsu H, Yamashita H, Noma H et al (2002) Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol 133:70\u201377","journal-title":"Am J Ophthalmol"},{"key":"2870_CR37","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1471-2415-14-67","volume":"14","author":"H Noma","year":"2014","unstructured":"Noma H, Mimura T, Shimada K (2014) Role of inflammation in previously untreated macular edema with branch retinal vein occlusion. BMC Ophthalmol 14:67","journal-title":"BMC Ophthalmol"},{"key":"2870_CR38","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/1471-2415-13-78","volume":"13","author":"H Noma","year":"2013","unstructured":"Noma H, Mimura T, Tatsugawa M, Shimada K (2013) Aqueous flare and inflammatory factors in macular edema with central retinal vein occlusion: a case series. BMC Ophthalmol 13:78","journal-title":"BMC Ophthalmol"},{"key":"2870_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2022.101727","volume":"28","author":"M Saito","year":"2022","unstructured":"Saito M, Kobori H, Nozuki N et al (2022) A case of intraocular inflammation after intravitreal brolucizumab injection monitored by laser flare-cell photometer. Am J Ophthalmol Case Rep 28:101727","journal-title":"Am J Ophthalmol Case Rep"},{"key":"2870_CR40","doi-asserted-by":"publisher","first-page":"e1043","DOI":"10.1111\/aos.13821","volume":"96","author":"C Taipale","year":"2018","unstructured":"Taipale C, Lindholm J-M, Tuuminen R (2018) Aqueous flare as a marker of retinal disease activity after anti-VEGF injections. Acta Ophthalmol 96:e1043\u2013e1044","journal-title":"Acta Ophthalmol"},{"key":"2870_CR41","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1111\/aos.15124","volume":"100","author":"M Busch","year":"2022","unstructured":"Busch M, Pfeil JM, D\u00e4hmcke M et al (2022) Anti-drug antibodies to brolucizumab and ranibizumab in serum and vitreous of patients with ocular disease. Acta Ophthalmol 100:903\u2013910","journal-title":"Acta Ophthalmol"},{"key":"2870_CR42","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1097\/IAE.0000000000001061","volume":"36","author":"A Hautam\u00e4ki","year":"2016","unstructured":"Hautam\u00e4ki A, Luoma A, Immonen I (2016) Anterior chamber flare during bevacizumab treatment in eyes with exudative age-related macular degeneration. Retina 36:2183\u20132190","journal-title":"Retina"},{"key":"2870_CR43","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1189\/jlb.1102574","volume":"74","author":"JW Streilein","year":"2003","unstructured":"Streilein JW (2003) Ocular immune privilege: the eye takes a dim but practical view of immunity and inflammation. J Leukoc Biol 74:179\u2013185","journal-title":"J Leukoc Biol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-023-02870-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-023-02870-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-023-02870-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T16:05:05Z","timestamp":1702656305000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-023-02870-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,3]]},"references-count":43,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2870"],"URL":"https:\/\/doi.org\/10.1007\/s10792-023-02870-4","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,3]]},"assertion":[{"value":"10 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}